ACTRN12618001304224尚未招募不适用
A Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase II Study to Assess the Opioid-Sparing Activity of PAX-1 in Patients with Persistent Cancer Pain.
Komipharm International Australia0 个研究点目标入组 240 人开始时间: 2018年8月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
3 期
OlympiABreast CancerJPRN-jRCT2080222553AstraZeneca KK144
尚未招募
2 期
A Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson’s DiseaseParkinson’s DiseaseNeurological - Parkinson's diseaseACTRN12623000843651niversity of Sydney240
尚未招募
2 期
Study of PAX-1 in Patients With Persistent Cancer Pain in the Palliative SettingACTRN12615000987561Bio And Gene Pty Ltd120
进行中（未招募）
不适用
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients with Social Anxiety Disorder (SAD)Subjects with Social Anxiety Disorder (SAD)EUCTR2004-001894-24-DEGlaxoSmithKline Research & Development Limited204
招募中
2 期
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s DiseaseParkinson’s DiseaseNeurological - Parkinson's diseaseACTRN12620000560998niversity of Sydney240